SLC5A2 and autosomal dominant polycystic kidney disease: These preliminary studies do not support the use of SGLT2 inhibition for kidney preservation in ADPKD at this time and may even sway clinicians to choose other hypoglycemic treatments in those patients with diabetes and ADPKD.